Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years. 27 July 2024
Vividion Therapeutics, a wholly-owned subsidiary of Germany’s Bayer, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. 23 July 2024
US pharm major Eli Lilly on Friday revealed via a social media posting that it has been granted approval from the Chinese National Medical Products Administration (NMPA) to sell tirzepatide for weight loss in the country. 20 July 2024
The US Food and Drug Administration (FDA) issued a draft guidance for industry, “Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment,” to help sponsors in the clinical development of drugs to treat pediatric patients with inflammatory bowel disease (IBD). 19 July 2024
Bristol-Myers Squibb has outlined the executive team that will take the newly-enlarged firm forward after its acquisition of rival oncology specialist Celgene. 5 June 2019
Patients must always be the center around which the entire innovation process revolves, while seeking to satisfy unmet patient needs, writes Alfredo Barón de Juan, Executive Vice President, Global Commercial Operations at Almirall, in an Expert View piece. 5 June 2019
Swiss pharma giant Novartis has presented results from the COMBI-d and COMBI-v trials, testing a combination of Tafinlar (dabrafenib) and Mekinist (trametinib), at the 2019 ASCO annual meeting. 5 June 2019
Clinical trial results reveal that a medication used to treat Alzheimer’s disease may also be an effective therapy for individuals addicted to opioids. The findings are published in The American Journal on Addictions. 5 June 2019
May marked a return to form for M&A activity after a quiet April, with some of pharma's biggest companies looking to bolster their pipelines through acquisitions. 4 June 2019
The US Food and Drug Administration (FDA) has accepted the New Drug Application for the investigational fixed-dose combination tablet of empagliflozin, linagliptin and metformin extended release (XR) for the treatment of adults with type 2 diabetes. 4 June 2019
Privately-held Danish medical dermatology specialist LEO Pharma today announced that Gitte Aabo will step down as president and chief executive after 27 years in the company, 11 of which were as CEO. 4 June 2019
Anglo-Swedish pharma major AstraZeneca and US drug giant Merck & Co have presented further evidence in support of Lynparza (olaparib) at the 2019 ASCO meeting. 4 June 2019
The US Food and Drug Administration today approved a new indication for the previously FDA-approved drug, Zerbaxa (ceftolozane and tazobactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years and older. 4 June 2019
Patients should get more of a say on the drugs that their taxes pay for, states one of the recommendations in a report launched in Australia on Monday. 3 June 2019
Japan’s Takeda Pharmaceutical has presented new data for TAK-788 during an oral session at the 2019 American Society of Clinical Oncology (ASCO) annual meeting. 3 June 2019
An interim analysis of the Phase III ENZAMET trial has found that 80% of men with metastatic hormone-sensitive prostate cancer who received Xtandi (enzalutamide) along with standard-of-care treatment were alive at three years. 3 June 2019
A trade group representing pharma in Hungary is trying to take a more proactive approach to improving cancer outcomes in light of a survey showing scope for improvement in the central European country. 3 June 2019
The new Medicines Law & Policy series of briefing documents, European Union Review of Pharmaceutical Incentives: Suggestions for Change, aims to contribute to the discussion on high medicines prices, in particular those that result from market exclusivity. 3 June 2019
Swiss pharma giant Novartis has released data showing statistically-significant overall survival (OS) results for the CDK4/6 inhibitor Kisqali (ribociclib), in combination with endocrine therapy. 3 June 2019
Jazz Pharmaceuticals today announced the appointment of Dr Robert Iannone as executive vice president, research and development, effective May 29, 2019. 3 June 2019
The UK subsidiary of French drug major Sanofi today announced the launch of Toujeo (insulin glargine 300 units/mL) DoubleStar, a new long-acting insulin glargine injection pen recommended for adults with type 1 or type 2 diabetes mellitus, who require at least 20 units of basal insulin per day. 3 June 2019